With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies have emerged in recent years on a mission to simplify production for the ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
SOUTH SAN FRANCISCO, Calif. & SEATTLE, July 13, 2026--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...
Cell and gene therapy manufacturing relies on complex cell processing, viral vector production, quality control, and GMP-compliant workflows to consistently produce safe and effective therapies at ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
DUBLIN and TORONTO, June 15, 2026 /CNW/ - CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited ("Avectas") to evaluate its automated, integrated and scalable ...
Artificial intelligence could revolutionize cell therapy manufacturing, but the industry needs to get better at gathering and handling data according to an expert, who says companies must stop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results